FITC-geldanamycin

Product Image: FITC-geldanamycin [NB610-81561] - Chemical structure of Geldanamycin- FITC (NB610-81561), a Hsp90 inhibitor. Molecular Formula: C55H63N5O13S. Molecular Weight: 560.6 g/mol.

• Applications: NULL

FITC-geldanamycin Summary

• Description: Hsp90 fluorescent probe

Applications/Dilutions

• Dilutions:
  • Product Image
• Application Notes: Purple solid. Soluble in DMSO (>10 mg/mL).

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.

Background

Geldanamycin is a benzoquinoid ansamycin produced by Streptomyces hygroscopicus. It binds specifically to heat shock protein HSP90 and downregulates target proteins including tyrosine kinases, steroid receptors, transcription factors and cell cycle regulatory kinases (1, 2). It induces the inactivation, destabilization and eventual degradation of HIF-1 alpha (3). It is also an inhibitor of pp60src tyrosine kinase and of c-myc gene expression in murine lymphoblastoma cells. It inhibits the transforming activity of abl, erbB, fps, src, and yes (4). Geldanamycin is capable of destabilizing several oncogene and proto-oncogene products; it is a potent inhibitor of the nuclear hormone receptor family (5). It protects against alpha-synuclein toxicity to dopaminergic neurons in Drosophila, and destabilizes mutant p53 protein from a number of breast, leukemic, and prostate cell lines (6). Inhibits basal and hypoxia-induced expression of c-Jun (IC50=75 nM) and abolishes hypoxia-induced increase in c-Jun N-terminal kinase (JNK) activity. Inhibits telomerase activity through inhibition of HSP90, a chaperone required for the assembly and activation of telomerase in human cells (6). It is ~10-fold more potent than herbimycin A. Specifically, the geldanamycin fluorescent probe may be used for detection of cell surface Hsp90, may be used in fluorescence polarization assays, and characterizations of geldanamycin drug-target interactions.

1. Whitesell L., et al. (1994) Proc. Natl. Acad. Sci. USA 91:8324.
2. Neckers L. (2002) Trends Mol. Med. 8: S55.
3. Mabjeesh N.J., et al. (2002) Cancer Res. 62: 2478.
4. Chavany C., et al. 1996) Amer. Society Biochem Mol Bio. 9: 4974-4977.
5. Villa R., et al. (2003) Carcinogenesis. 24(5): 851-9.
6. Yamaki H., Iguchi-Ariga S.M., and Ariga H. (1989) J Antibiot (Tokyo). 42(4): 604-10.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Support products are guaranteed for 6 months from date of receipt.